The use of TNF inhibitors during pregnancy is not associated with worse fetal or obstetric outcomes

According to new research at ACR Convergence 2023, the annual meeting of the American College of Rheumatology (ACR), use of tumor necrosis factor inhibitors during pregnancy is not associated with worse fetal or obstetric outcomes and may reduce the risk of serious maternal infections during pregnancy ( Abstract #0477). Tumor necrosis factor (TNF) inhibitors such…